208 related articles for article (PubMed ID: 32283222)
21. Curcumin Combination Chemotherapy: The Implication and Efficacy in Cancer.
Tan BL; Norhaizan ME
Molecules; 2019 Jul; 24(14):. PubMed ID: 31295906
[TBL] [Abstract][Full Text] [Related]
22. Piperlongumine induces apoptotic and autophagic death of the primary myeloid leukemia cells from patients via activation of ROS-p38/JNK pathways.
Xiong XX; Liu JM; Qiu XY; Pan F; Yu SB; Chen XQ
Acta Pharmacol Sin; 2015 Mar; 36(3):362-74. PubMed ID: 25619389
[TBL] [Abstract][Full Text] [Related]
23. Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells.
Yao Y; Sun Y; Shi M; Xia D; Zhao K; Zeng L; Yao R; Zhang Y; Li Z; Niu M; Xu K
Oncotarget; 2016 Nov; 7(45):73497-73508. PubMed ID: 27634873
[TBL] [Abstract][Full Text] [Related]
24. Preformulation Studies on Piperlongumine.
Aodah A; Pavlik A; Karlage K; Myrdal PB
PLoS One; 2016; 11(3):e0151707. PubMed ID: 26982320
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic applications of curcumin for patients with pancreatic cancer.
Kanai M
World J Gastroenterol; 2014 Jul; 20(28):9384-91. PubMed ID: 25071333
[TBL] [Abstract][Full Text] [Related]
26. Piperlongumine induces apoptosis and autophagy in leukemic cells through targeting the PI3K/Akt/mTOR and p38 signaling pathways.
Wang H; Wang Y; Gao H; Wang B; Dou L; Li Y
Oncol Lett; 2018 Feb; 15(2):1423-1428. PubMed ID: 29434833
[TBL] [Abstract][Full Text] [Related]
27. Vinflunine: clinical perspectives of an emerging anticancer agent.
Yun-San Yip A; Yuen-Yuen Ong E; Chow LW
Expert Opin Investig Drugs; 2008 Apr; 17(4):583-91. PubMed ID: 18363522
[TBL] [Abstract][Full Text] [Related]
28. Piperlongumine chemosensitizes tumor cells through interaction with cysteine 179 of IκBα kinase, leading to suppression of NF-κB-regulated gene products.
Han JG; Gupta SC; Prasad S; Aggarwal BB
Mol Cancer Ther; 2014 Oct; 13(10):2422-35. PubMed ID: 25082961
[TBL] [Abstract][Full Text] [Related]
29. Piperlongumine Induces Reactive Oxygen Species (ROS)-Dependent Downregulation of Specificity Protein Transcription Factors.
Karki K; Hedrick E; Kasiappan R; Jin UH; Safe S
Cancer Prev Res (Phila); 2017 Aug; 10(8):467-477. PubMed ID: 28673967
[TBL] [Abstract][Full Text] [Related]
30. Piperlongumine and some of its analogs inhibit selectively the human immunoproteasome over the constitutive proteasome.
Bosc E; Nastri J; Lefort V; Valli M; Contiguiba F; Pioli R; Furlan M; Bolzani VDS; El Amri C; Reboud-Ravaux M
Biochem Biophys Res Commun; 2018 Feb; 496(3):961-966. PubMed ID: 29355526
[TBL] [Abstract][Full Text] [Related]
31. Advances in the Anticancer Value of the Ursolic Acid Through Nanodelivery.
Manayi A; Nikan M; Nobakht-Haghighi N; Abdollahi M
Curr Med Chem; 2018; 25(37):4866-4875. PubMed ID: 28707589
[TBL] [Abstract][Full Text] [Related]
32. Piperlongumine inhibits the proliferation and survival of B-cell acute lymphoblastic leukemia cell lines irrespective of glucocorticoid resistance.
Han SS; Han S; Kamberos NL
Biochem Biophys Res Commun; 2014 Sep; 452(3):669-75. PubMed ID: 25193702
[TBL] [Abstract][Full Text] [Related]
33. Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells.
Shrivastava S; Kulkarni P; Thummuri D; Jeengar MK; Naidu VG; Alvala M; Redddy GB; Ramakrishna S
Apoptosis; 2014 Jul; 19(7):1148-64. PubMed ID: 24729100
[TBL] [Abstract][Full Text] [Related]
34. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties.
Kruczynski A; Hill BT
Crit Rev Oncol Hematol; 2001 Nov; 40(2):159-73. PubMed ID: 11682323
[TBL] [Abstract][Full Text] [Related]
35. Using Sensors and Generators of H2O2 to Elucidate the Toxicity Mechanism of Piperlongumine and Phenethyl Isothiocyanate.
Huang BK; Langford TF; Sikes HD
Antioxid Redox Signal; 2016 Jun; 24(16):924-38. PubMed ID: 26905788
[TBL] [Abstract][Full Text] [Related]
36. Piperlongumine induces ROS mediated cell death and synergizes paclitaxel in human intestinal cancer cells.
Rawat L; Hegde H; Hoti SL; Nayak V
Biomed Pharmacother; 2020 Aug; 128():110243. PubMed ID: 32470748
[TBL] [Abstract][Full Text] [Related]
37. Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma.
Golovine K; Makhov P; Naito S; Raiyani H; Tomaszewski J; Mehrazin R; Tulin A; Kutikov A; Uzzo RG; Kolenko VM
Cancer Biol Ther; 2015; 16(5):743-9. PubMed ID: 25801713
[TBL] [Abstract][Full Text] [Related]
38. Targeting silibinin in the antiproliferative pathway.
Li L; Zeng J; Gao Y; He D
Expert Opin Investig Drugs; 2010 Feb; 19(2):243-55. PubMed ID: 20047507
[TBL] [Abstract][Full Text] [Related]
39. Back to basics: how natural products can provide the basis for new therapeutics.
Deorukhkar A; Krishnan S; Sethi G; Aggarwal BB
Expert Opin Investig Drugs; 2007 Nov; 16(11):1753-73. PubMed ID: 17970636
[TBL] [Abstract][Full Text] [Related]
40. Chitosan-loaded piperlongumine nanoparticles and kaempferol enhance the anti-cancer action of doxorubicin in targeting of Ehrlich solid adenocarcinoma: in vivo and in silico modeling study.
Ibrahim FAR; Hussein NA; Soliman AYM; Shalaby TI; Rashad MM; Matar NA; El-Sewedy TS
Med Oncol; 2024 Jan; 41(2):61. PubMed ID: 38253759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
